Ensysce Biosciences to present on PF614-MPAR at NIH HEAL Meeting

Ensysce Biosciences announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will present a poster entitled “PF614-MPAR: A Novel Trypsin Activated Abuse Protected Extended-Release Oxycodone Prodrug with Overdose Protection” at the Annual National Institutes of Health “Helping to End Addiction Long-term” Initiative Scientific Meeting being held on February 7 and 8, 2024, in Bethesda, MD. PF614-MPAR, the lead product under Ensysce’s oral overdose protection platform, MPAR, was just granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration and has been supported by funding from the National Institute on Drug Abuse. The endorsements by both agencies have aided the clinical development of the first opioid with both abuse deterrent properties and importantly, oral overdose protection. We believe that no opioid on the market has these dual properties. The trial being presented was undertaken to optimize the PF614-MPAR combination drug product and successfully met its overdose protection endpoints.